Lucatumumab

Source: Wikipedia, the free encyclopedia.
Lucatumumab
CD40
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Molar mass146 kg/mol
 ☒NcheckY (what is this?)  (verify)

Lucatumumab (CHIR 12.12 or HCD122)

CD40[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.[3]

It is an antagonist to CD40 that was created by scientists at

transgenic mouse to generate fully human antibodies.[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.[6][7][8] Novartis took over the project when it acquired Chiron in 2005.[9][10]

In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.[11]

Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.[1]

References

  1. ^
    S2CID 21840914
    .
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
  3. ^ "Lucatumumab". AdisInsight. Retrieved 20 February 2017.
  4. ^ "Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference". XOMA and Chiron vis Businesswire. December 2, 2004.
  5. ISSN 0006-4971
    .
  6. ^ "Chiron and Xoma in MAb deal - Pharmaceutical industry news". The Pharma Letter. March 8, 2004.. Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.
  7. ^ "Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA". Xoma via SEC Edgar.
  8. ^ "Exhibit 10.2 Amended Research, Development and Commercialization Agreement". www.sec.gov. Xoma via SEC Edgar. May 26, 2005.
  9. ^ Tansey B (November 1, 2005). "Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion". San Francisco Chronicle.
  10. ^ "Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)". Xoma. November 10, 2008. Archived from the original on February 20, 2017. Retrieved February 20, 2017.
  11. ^ "Lucatumumab". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02. Retrieved 20 February 2017.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lucatumumab&oldid=1192895561"